National Institutes of Health (NIH): Intramural Research Program (IRP)

Researchers at The National Institutes of Health's Center for Alzheimer’s and Related Dementias are trying to connect the dots between changes in DNA and the death of neurons in the brain. These findings could help improve our understanding of Alzheimer’s disease and related forms of #dementia and pave the way for more effective treatments. Read on to learn more: https://go.nih.gov/i8nQ6Ah #NIH_IRP

Suzie Stephenson, a postdoc fellow at The National Institutes of Health, is researching how a particular virus sabotages cells in the liver. Understanding this process could lead to new treatments or even a cure for a potentially lethal liver disease. Watch the full #SciBites video here: https://go.nih.gov/3SBAHqS #NIH_IRP

This week’s #NIH_WALS, we welcome Dr. Brenda Gallie, of the University of Toronto and The Hospital for Sick Children, a leading expert in the field of #ophthalmology and #retinoblastoma. Dr. Gallie will discuss Disease-specific Electronic Patient Illustrated Clinical Timeline (#DePICT), which graphically displays all the disease-specific care for patients with retinoblastoma. Tune in on 12/18 at 2 pm ET: https://go.nih.gov/eMmxBZt.

Scientists at The National Institutes of Health are exploring if #Ozempic, the diabetes medication that has garnered widespread attention over the last few years, could be used to treat patients battling substance use disorder. Dr. Lorenzo Leggio at The National Institute on Drug Abuse (NIDA) is exploring the addiction-reduction potential of semaglutide, Ozempic's active ingredient. Read more about how the unexpected connection can expand treatment options for people battling substance use disorder: https://go.nih.gov/alxPR3W. #NIH_IRP

Parkinson’s disease stems from the death of ‘dopaminergic’ neurons in the brain. Without these neurons, our bodies have trouble initiating and controlling movements. #NIH_IRP researchers, Dr. Yihong Ye at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Drs. Wei Zheng and Qi Zhang at the National Center for Advancing Translational Sciences (NCATS), have identified a promising new approach that could be used for slowing or stopping the progression of movement problems that affect people with Parkinson’s disease. Learn more: https://go.nih.gov/QGeVFjJ

We’re thrilled to announce that The University of Texas at Austin's Dr. Jason McLellan will present the prestigious Rolla E. Dyer Lecture as part of The National Institutes of Health Wednesday Afternoon Lecture Series! Dr. McLellan, a leading expert in viral structure and resistance, will share groundbreaking insights into his research on viral proteins and antiviral strategies that are paving the way for more effective vaccines and treatments, especially in the fight against global health threats like COVID-19. Join us on Wednesday, December 11, 2024, at 2pm ET: go.nih.gov/aJWRtnF #NIH_WALS. This is a must-attend for anyone passionate about science, global health, and the future of infectious disease research. #InfectiousDiseases #PublicHealth #InnovationInScience

Join us Wednesday, December 4 at 2 p.m. ET for a special Director's Lecture featuring Caltech's Dr. William Clemons, a leading expert in structural biology and biochemistry: https://go.nih.gov/RTptThI Dr. Clemons will discuss how some phages have developed simple, protein-based mechanisms for breaking through the bacterial cell wall and killing their host. Don't miss this opportunity to hear from one of the brightest minds in the field. Bring your curiosity and questions! #NIH_WALS #Biochemistry #StructuralBiology #InnovativeScience #MedicalResearch #HealthcareInnovation #ScienceMatters

In honor of #WorldAIDSDay yesterday, we're spotlighting cutting-edge research led by the National Cancer Institute (NCI)’s Dr. Barbara Felber that could revolutionize HIV prevention. Dr. Felber and her team are developing new vaccines that target the stable genetic core of HIV, a more consistent target than current HIV vaccines use. This innovative approach uses DNA/RNA vaccines and cytokines to enhance the immune system's ability to identify and neutralize the virus. The targeted approach offers the potential for a more effective and durable immune response, bringing us closer to an HIV-free future. The research also has exciting implications for other areas of immunotherapy, including cancer treatments. Learn more about this promising research and how it can contribute to HIV prevention: https://go.nih.gov/Z44IxUG #NIH_IRP

Meet the newest NIH Lasker Scholars: Drs. Chris Grunseich at National Institute of Neurological Disorders and Stroke (NINDS), Lisa McReynolds at National Cancer Institute (NCI) Division of Cancer Epidemiology & Genetics, Samira Sadowski at NCI Center for Cancer Research, and andrea lisco at National Institute of Allergy and Infectious Diseases (NIAID) are early-career physician-scientists who are working on new discoveries that could one day improve their patients’ lives. From investigating the roots of muscle-weakening genetic conditions to probing the mysteries of rare, hormone-producing tumors, learn about the cutting-edge research that each scholar is working on: https://go.nih.gov/YRsK6J2 #NIH_IRP

Epilepsy, addiction, autism—what do they have in common? Glycine receptors. Dr. Sudha Chakrapani at Case Western Reserve University School of Medicine will explore how understanding these receptors can lead to targeted therapies, Nov. 20 at 2 p.m. ET at The National Institutes of Health: https://go.nih.gov/2leZ7i4. #NIH_WALS #Neurobiology #DrugDevelopment